By Fineline Cube Stoke Therapeutics (NASDAQ: STOK) and Biogen Inc. (NASDAQ: BIIB) announced that they will present clinical data on zorevunersen for the treatment of Dravet syndrome at the 16th European Epilepsy Congress (EEC), taking place September 5–9 in Athens, Greece. The presentation will showcase more than 5 years of clinical experience with the antisense oligonucleotide candidate, including four-year open-label extension results demonstrating substantial and durable seizure reductions alongside continuing cognitive and behavioral improvements.
Presentation Overview
| Item | Detail |
|---|---|
| Companies | Stoke Therapeutics (NASDAQ: STOK) and Biogen Inc. (NASDAQ: BIIB) |
| Product | zorevunersen |
| Indication | Dravet syndrome |
| Venue | 16th European Epilepsy Congress (EEC), Athens, Greece |
| Congress Dates | 05–09 Sept 2026 |
| Announcement Date | 03 Sept 2026 |
| Data Scope | More than 5 years of clinical experience, including two Phase I/IIa studies and ongoing open-label extension studies (OLEs) |
Drug Profile & Mechanism
- Molecule: zorevunersen, an investigational antisense oligonucleotide being developed for Dravet syndrome, a severe and treatment-resistant developmental and epileptic encephalopathy
- Development Partners: Jointly advanced by Stoke Therapeutics and Biogen, combining Stoke’s RNA-targeting platform with Biogen’s neurology development and commercial scale
- Evidence Base: Clinical data span two Phase I/IIa studies and ongoing open-label extension studies (OLEs)
Clinical Evidence – Long-Term OLE Results
| Outcome | 4-Year OLE Finding |
|---|---|
| Seizure burden | Substantial and durable reductions |
| Cognition | Continuing improvements |
| Behavior | Continuing improvements |
The four-year OLE data represent the longest available follow-up on zorevunersen in Dravet syndrome patients. Beyond seizure control — the conventional primary metric in epilepsy trials — the sustained improvements in cognition and behavior address the broader developmental burden of the disease, a dimension where most existing therapies offer little meaningful benefit.
Market Impact & Outlook
- Durability as differentiator: Five-plus years of accumulating data strengthen the long-term efficacy and safety narrative for zorevunersen ahead of potential regulatory submissions
- Beyond seizures: Cognitive and behavioral gains could position the therapy as disease-modifying rather than purely symptomatic — a critical distinction for pricing, reimbursement and clinical adoption in rare epileptic encephalopathies
- Scientific visibility: Presentation at the European Epilepsy Congress puts the data directly in front of the treating neurologist community that drives prescribing decisions in Dravet syndrome
- Partnership momentum: The joint presentation reinforces the Stoke–Biogen alliance and Biogen’s continued investment in rare neurological disease franchises
Forward‑Looking Statements: This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding clinical data interpretation, regulatory pathways and commercial potential are forward-looking and subject to risks and uncertainties, including trial outcomes, regulatory decisions and competitive developments. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.-Fineline Info & Tech